Abstract
Background Xenon and argon inhalation were included in the WADA Prohibited List in 2014 due to the reported positive effects on erythropoiesis and steroidogenesis occurs as a result of the use of these substances. Currently, xenon is on the WADA Prohibited List notable affecting erythropoiesis as a Hypoxia-inducible factor (HIF) activating agent. At the same time, argon inhalation was allowed again in 2019. Thus, the systematic review of studies supporting these notions is of interest.
Methods A thorough search for articles on the effects of xenon and argon inhalation on erythropoiesis and steroidogenesis, as well as their negative effects on human health and methods of their detection in body fluids was conducted. Pubmed, Google Scholar databases and the Cochrane Library were researched, as well as the special research section of the WADA website. The search was conducted in accordance with PRISMA guidelines. All articles in English published between 2000 and 2021 were analyzed, as well as reference studies meeting the search criteria.
Results At present, there are only two publications in healthy human subjects evaluating the effects of xenon inhalation on erythropoiesis were found with no conclusive evidence of a positive effect on erythropoiesis. Both articles were published after 2014 when the gases were included on the WADA Prohibited List. Both articles had a high risk of bias. There were no studies on the effect of argon inhalation on erythropoiesis. No studies were found on the effect of xenon or argon inhalation on steroidogenesis in healthy subjects. No studies related to the effects of xenon or argon inhalation on erythropoiesis and steroidogenesis were found on the WADA website.
Conclusion There is still inconclusive evidence to support the administration of xenon and argon inhalations on erythropoiesis and steroidogenesis and their positive effects on health. Further research is needed to establish the effects of these gases. Additionally, improved communication between the anti-doping authorities and all key stakeholders is required to support the inclusion of various substances on the Prohibited List.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Methods and Results sections (more databases and libraries for research, some irrelevant information to remove)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
